Company Profile

Mytide Therapeutics Inc
Profile last edited on: 5/9/22      CAGE: 873M7      UEI: VADEX7QKGFK7

Business Identifier: Manufacture custom peptides for researchers: faster and at higher quality
Year Founded
2018
First Award
2020
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

451 D Street Suite 707
Boston, MA 02110
   (412) 225-5848
   hello@mytide.io
   www.mytide.io
Location: Single
Congr. District: 08
County: Suffolk

Public Profile

Describing their operations as Industrializing peptide manufacturing with machine learning for speed, purity, and scale, Mytide Therapeutics is structured around providing peptides to serve a diversty of applications., The firm is multi-disciplinary team of engineers, biochemists and computer scientists utilizing a technologically advanced approach to solving long-standing challenges in both peptide synthesis and purification. With the focus on accelerating discovery and development of life-saving peptide therapeutics for serious illnesses ranging from metabolic conditions to cancer to inflammatory disorders to infectious diseases, the firm's fully automated peptide manufacturing technology, coupled with predictive analytics and machine learning, is designed to challenge long standing paradigms to enable cost-efficient research and development, therapeutic manufacturing, and discovery.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NSF $359,892
Project Title: Solid Phase Slug Flow (SPSF) for Drug Discovery

Key People / Management

  Jason Norris

  Joel Nyberg -- Senior Scientist

  Dale Thomas -- Co-Founder

Company News

There are no news available.